Nimotuzumab

Description

Nimotuzumab(Taixinsheng) is a biologically targeted drug that acts on the epidermal growth factor receptor (EGFR) on the surface of tumor cells, inhibiting the proliferation and differentiation of tumor cells. It has the advantages of low reaction and good safety.
Suitable for head and neck tumors, gliomas, colorectal cancer, pancreatic cancer, esophageal cancer, liver cancer, non-small cell lung cancer and other solid tumors.

Uses

Nimotuzumab is a humanized IgG1 monoclonal antibody targeting EGFR with a KD of 0.21 nM. Nimotuzumab is directed against the extracellular domain of the EGFR blocking the binding to its ligands. Nimotuzumab, a strong antitumor agent, is cytolytic on target tumors by its capacity to cause antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC)[1][2].

Pharmacology

Nimotuzumab, as the first humanized monoclonal antibody in my country, can competitively bind to EGFR and block its conduction pathway, thereby inhibiting tumor cell proliferation and tumor angiogenesis, thereby enhancing the efficacy of radiotherapy and chemotherapy.

target

EGFR

References

[1] Zaima Mazorra, et al. Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients. Front Pharmacol. 2017 Jun 19;8:382. DOI:10.3389/fphar.2017.00382
[2] Melarkode S Ramakrishnan, et al. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. MAbs. Jan-Feb 2009;1(1):41-8. DOI:10.4161/mabs.1.1.7509